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care workers in the public service look beyond government
for funds to suppor AART for their patients. We need to
engage with foreign charities, the Global Fund against
tuberculosis, malaria and AIDS, and organisations like the
Treatment Aerion Campaign 0 Ind ways to help our
patients. Because HIV infection and AIDS are new to our
region we need new and additional sources of money and
not merely a redistribution of what was an inadequate
health care budget to start with.
Partnerships between foreign donors, local non-
governmental organisations [NGOs) and public service
hospitals offer a model [Fig. 11 through which indigent
patients can gain access to HAART. The foreign donor is the
source of funding. NGOs administer these funds and
account for expenditure to the donor. Public service
hospitals and clinics provide the staff and infrastructure.
Fig. 1. A parrnership ra deliver HAART in rhe public secrar
I Public Health Service Unit I
t t
Various forms of such partnerships already exist and have
enabled doctors at several public service hospitals to
initiate pilot HAART programmes. The benefit of these
partnerships is that they hasten access to treatment and
offer sites at which staff can be trained in the use of ARVs.
A potential harm of this model is that the pressure on
government ra proviae meaningful funding for HAART may
be lifted. Piior treatment programmes may permit aecision-
ANTIRETROVIRAL THERAPY FOR CHILDREN
IN THE PUBLIC HEALTH CARE SECTOR
Vertical transmission of the HIV from mother to child
accounts for the vast majority of HIV in'eerions seen in
Soutn African cnildren. Prevention 0' mother-ta-child
uansmission (pMTCT) is highly cost-e eerive in
comparison to nospital care of HIV-infec ed children,'; but
the cost and cost-e'lcacy of HAART in the local setting has
no yet been included in this calcula ion. If pMTCT
programmes are rolled OUt efficiently and if HAART
becomes available for use during pregnancy, we may expect
mo her,to-child transmission rates of less than 10f0. Far
fewer children would need HAART and the overall cost may
be more acceptable to many.
In the absence of efficient pMTCT, paediatric services
countrywide have seen steep increases in admissions and
outpatient visits for HIV-related infections during the past
decade, even in provinces with lower rates of adult
infection.' Where children have reasonable access to health
care, a considerable number follow a chronic disease
course: require recurrent hospital admissions and present
an increasing burden of COSt' to the public health service.
At present the right o· HIV-infeerea children to 'standard of
care' rl'aragemenr, incluaing HAART, is void unless health
FUNDS FOR ARVs TO TREAT CHILDREN IN THE
, PUBUC SECTOR
Because of the South African governmental health
policy, which does nor permit public health service
access to antireuoviral drugs (ARVs), he use of these
drugs has been restricted to clinical trials and to the
upper tier of health care services in South Africa, i.e.
patients who have health care insurance or other means
to purchase drugs. Clinical experience with ARVs has
been restricted to physicians in private practice and
those engaged in drug trials. Since South African
children have rarely been enrolled as subjects in drug
trials, few local paediatricians in hospital or academic
practice have been able to gain experience in using
highly active antiretroviral therapy [HAARD. Moreover,
few public health care institutions, whether urban or
rural, have yet developed the sort of dedicated,
comprehensive clinical HIV service that is an essential
precondition for the successful introduction of HAART.
makers to delay the roll-out of definitive services.
Besides their obvious benefits to infected children, HAART
pilot projects are useful for other reasons. While it is true
that many patients with HIV infection,' and indeed simple,
first-line HAART regimens, could be managed at primary
care level, many paediatricians and paediatricians in
training feel themselves inadequate to manage infected
children.' Pilot programmes offer an opportunity for health
care workers to set up the necessary structures to provide
comprehensive care, to acquire the necessary expertise and
familiarity with treatment regimens, and to gain
operational insights into practical requirements for
successful management with ARVs. Pilot programmes will
provide essential information on what facilities and staff
are required to prescribe, dispense and promote adherence
to HAART regimens in the public service.
WHICH CHILDREN SHOULD BE TREATED
The updated Southern African HIV Clinicians Society
guidelines for the management of HIV infection in children
list clinical category B or C disease and/or a CD4+
percentage below 20% of the age norm as indications for
starting HAART. These guidelines are valid for children
attending public service clinics and hospitals.
The cost of laboratory tests to confirm the diagnosis and
time the initiation of therapy is a problem for
implementing HAART in the public service. A polymerase
chain reaction (PCR]-based test to make a definitive
diagnosis of HIV infection before starting treatment in
children under 18 months old is indispensable. A correct
assessment of immunosuppression is difficult without
access to CD4+ counts. A recent study has shown 85% of
'stable' infected children to be moderately or severely
immunosuppressed." There is some evidence for a positive
correlation between CD4+ and total Iymphocyte count. It
would therefore seem reasonable to consider HAART in any
child with category B or C disease and/or a low total
Iymphocyte count as a candidate for HAART.
As is the case with adults, starting treatment is seldom an
emergency in children. However, since growth and
development are impaired in the majority of HIV-infected
children, and since both of these problems respond to
HAART,'·w there seems to be more urgency to start
treatment in the paediatric setting.
Patients with HIV infection attending public service
institutions are at high risk of infection with
Mycobacterium tuberculosis. Children who are receiving
treatment for tuberculosis when first considered for HAART
should complete TB therapy before starting treatment with
ARVs if their immunity is moderately suppressed. Those
with severe immunosuppression should preferably
complete 2 months of intensive TB therapy before starting
their HAART regimen. This reduces [he chances of shared
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toxicity and a paradoxical worsening of TB with immune
reconstitution. Children who are profoundly
immunosuppressed should first start and be seen to
tolerate antituberculosis therapy before starting
antiretroviral therap{'
RATIONING OF ACCESS TO A UMITED TREATMENT
RESOURCE
A limited number of children can be treated in charity-
funded pilot programmes. The approach shared by several
such programmes is to allocate HAART according to a
queuing system: One treats those children who meet a set
of inclusion criteria (based on the HIV Clinicians Society
guidelines) and closes admission to the programme once
the full budget and all available treatment slots have been
allocated.
Some pilot clinics have elected to treat mothers and
children in pairs. The reasoning behind such a decision is
clear, but because the course of HIV infection in mother
and child is so often asynchronous and because the disease
generally runs a faster course in children, this approach
may mean that many well mothers will have to watch their
children die.
CHOICE OF A TREATMENT REGIMEN
The Southern African HIV Clinicians Society guidelines for
ARVs in children provide a complete list of drugs available
for children and recommendations regarding the
combinations to be used. A first-line three-drug regimen
should include a 'backbone' of two nucleoside reverse
transcriptase inhibitors (NRTls] together with either a
protease inhibitor (PI) or a non-nucleoside reverse
transcriptase inhibitor (NNRTI). Because children often
have very high viral loads at diagnosis that are frequently
not suppressed to undetectable levels, there is a high risk
that resistant strains of virus will arise. Since NNRTI
resistance requires a single mutation, the choice of a PI to
complete a three-drug regimen may be preferable.
Most drugs are more expensive as paediatric suspensions
than in tablet, powder or capsule form. Some
paediatricians, driven by cost constraints, treat children
with tablets that their caregivers are required to crush and
suspend in carefully measured volumes of water before
administration. The unfortunate paradox is that the home
environments of the poorest patients tend not to have the
space or facilities for such relatively complex preparations.
Hence children attending public service clinics probably
need the more expensive ready-made suspensions and the
(also more expensive) simplest daily regimens - if their
caregivers are to adhere to treatment. The majority of
charity-funded HAART programmes have opted for
relatively expensive, but simple, suspension-based
regimens.
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ADHERENCE TO HAART REGIMENS IN CHILDREN
HAART can achieve control of viral replication in HIV-l-
infected children who adhere to therapy" Medicine that is
difficult to prepare or unpalatable is less likely IQ be
administered to the child" If caregivers are not prepared
for adherence before starting HAART, or if regimens are too
onerous to follow (Table I), treatment is likely to fail.




• Problems around meals
• Non-disclosure to others
• Hiding or re-labelling medicines
• Defaults at clinic
• Midday doses
Every effort should be made to see the burden of adherence
from the caregiver's point of view. Meticulous attention to
detail offers the greatest likelihood of making HAART a
successful joint venture (Table 11). The key to adherence lies
in the amount of time and care the health care worker can
devote to the effort of explaining the purpose and practice
of adherence.
TABLE 11. STRATEGIES FOR THE PROMOTION OF ADHERENCE
TO PAEDIATRIC HAART REGIMENS
• Promote demand rather than adherence
• Encourage maternal self-esteem
• Cohort bookings to promote alliance between mothers
• Buddy system for 'reciprocal DOTS' reward for good
performance
• Promote pride in access, therapeutic programmes. national
success
• Access technology: 'Adapracaps', syringes
• Training in medication
• Preparatory visits to the clinic
• Cues, reminders, diary cards
• Social and community support
• TIme from health care workers
MONITORING THE RESPONSE TO TREATMENT
Tests to monitor immunological and viral responses to
HAART are becoming less expensive, though still beyond
what the public service can afford. There is at least some
evidence that clinical response'" is a reasonable proxy for
CD4+ counts and viral loads. These findings need to be
confirmed by operational research in the southern African
setting.
There are as yet no reports in the literature regarding the
success of local paediatric programmes, and most have not
been running long enough with sufficient patients for
analysis.
SUMMARY AND CONClUSIONS
Current Sou h African government health policy does nor
permi: nerapy with antire roviral drugs in pub,ic service
hospitals or clinics. Given the size of the AIDS epidemic in
South Africa and the very many South African health care
workers who have experienced the morbidity and mortality
among their patients, it is remarkable and disquieting that
there has not been more protest from the medical
fraternity against government policy regarding public
access to antiretroviral therapy. History will no doubt
question the silence of so many.
Health care workers managing HIV-infected children must
become more active in gaining access to HAART for their
patients. Successful partnerships between foreign donors,
local NGOs and public service facilities offer models for
projects to pilot HAART for children and to provide
experience and training for health care workers.
Complex regimens and problems with adherence are
obstacles to the successful use of HAART in children
managed in the public service - but can be overcome. A
low-price HAART regimen, if it adds complexity to
administration, is not necessarily the cheapest option.
Government, health authorities and heads of academic
departments must commit sufficient space and human
resources to develop paediatric HIV!AIDS services so that
they can become viable platforms for the delivery of
HAART. Services should be initiated as pilot projects at all
levels of health care delivery, so that units in rural areas can
develop in partnership with urban and academic services
that can support them. Each pilot project should include
elements of audit and operational research, so that in the
process of implementation, all practice can be measured
and assessed as services are delivered.
The cost of a su"icient, dedicated and rob st health care
service will be significant, but such a service must be
established as soon as possible.
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